Abstract

CO183 Simulated Treatment Comparison and Matching-Adjusted Indirect Comparison of the Efficacy of Eplontersen and Vutrisiran for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
The Use Of Matching Adjusted Indirect Comparison (MAIC) And Simulated Treatment Comparison (STC) In Hta Submissions; Learnings From Recent Submissions
N Pooley ... E Adkins
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. 20
N Pooley, et. al.N Pooley ... E Adkins
01 Oct 2017
Indirect Treatment Comparison (ITC) of Inotuzumab Ozogamicin (InO) and Blinatumomab (Blina) for Relapsed or Refractory (RR) Acute Lymphoblastic Leukemia (ALL)
Matthias Stelljes ... Irina Proskorovsky
Blood | VOL. 130
Matthias Stelljes, et. al.Matthias Stelljes ... Irina Proskorovsky
25 Jun 2021
Evaluation of methodologies for indirect comparison of eplontersen and vutrisiran for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy (P12-4.005)
Chafic Karam ... Gengshi Chen
Neurology | VOL. 100
Chafic Karam, et. al.Chafic Karam ... Gengshi Chen
25 Apr 2023
P1061: INDIRECT TREATMENT COMPARISONS OF FEDRATINIB VERSUS NAVITOCLAX PLUS RUXOLITINIB: EFFECT ON SPLEEN VOLUME AND SYMPTOMS IN RUXOLITINIB-EXPOSED MYELOFIBROSIS PATIENTS
P Abraham ... X Liao
HemaSphere | VOL. 6
P Abraham, et. al.P Abraham ... X Liao
23 Jun 2022
View more papers

More From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Paper Title
Journal
Date
Author
The Functional Assessment of Cancer Therapy Eight Dimension (FACT-8D), a Multi-Attribute Utility Instrument Derived From the Cancer-Specific FACT-General (FACT-G) Quality of Life Questionnaire: Development and Australian Value Set
-
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. -
--
21 Jun 2024
Market entry agreements for innovative pharmaceuticals subject to indication broadening: a case study for pembrolizumab in the Netherlands.
Renaud J S D Heine ... Carin A Uyl-De Groot
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. -
Renaud J S D Heine, et. al.Renaud J S D Heine ... Carin A Uyl-De Groot
21 Jun 2024
MSR99 A Stacked Ensemble Approach for Building Composite Measure Models in Healthcare
P Shi ... S Zhang
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. 27
P Shi, et. al.P Shi ... S Zhang
15 Jun 2024
EE98 A Theory-Based Framework to Incorporate Health Equity in Economic Assessments
S Subramanian ... S Hoover
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. 27
S Subramanian, et. al.S Subramanian ... S Hoover
15 Jun 2024
View more papers